Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio Starts China Trials of Gastric Cancer Therapy

publication date: Aug 25, 2021

LianBio, a Shanghai-Princeton in-licensing company, has started a China Phase IIa trial of infigratinib, an FGFR2 inhibitor. The trial will enroll patients who have gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification. One year ago, LianBio acquired China rights to the candidate from BridgeBio as part of a two-drug, $531 million agreement. Infigratinib, which is approved in the US to treat cholangiocarcinoma with a FGFR2 fusion, is the first LianBio asset to start clinical trials. More details....

Stock Symbol: (NSDQ: BBIO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.